Edwards Lifesciences
EW
$94.44
+2.90%
Edwards Lifesciences is a global medical device company focused on structural heart disease, designing and marketing surgical tissue heart valves, transcatheter aortic valve replacement (TAVR) systems, and transcatheter mitral and tricuspid therapies, with roughly 60% of sales generated outside the US. Spun off from Baxter International in 2000, the firm has established itself as the dominant pure-play leader in transcatheter heart valves, a position built on clinical evidence, physician training, and first-mover scale in a market where procedural adoption is still expanding globally. The current investor narrative centers on a beat-and-raise fundamental backdrop, with TAVR demand driving double-digit top-line growth and a proposed US agency expansion of Medicare coverage for TAVR procedures acting as a meaningful regulatory tailwind that could broaden the eligible patient pool. At the same time, debate persists around the pace of margin recovery after a noisy 2025, the heavy R&D investment required to build out mitral and tricuspid franchises, and whether the premium multiple is justified by the durability of TAVR growth against emerging competition.…
EW
Edwards Lifesciences
$94.44
Related headlines
Investment Opinion: Should I buy EW Today?
We rate EW a Buy, based on its dominant position in the growing TAVR market, double-digit revenue growth, and a potential Medicare coverage expansion that could significantly broaden the patient pool. The analyst consensus is 'buy' with a mean rating of 1.63 and an average target price of $101.39, implying 13.8% upside from the current $89.07. The core thesis is that Edwards will continue to grow revenue at a low-to-mid-teens pace, driven by TAVR adoption and new product launches, while maintaining industry-leading margins.
The supporting evidence is strong: Q2 2026 revenue grew 13.63% YoY to $1.741 billion, with TAVR contributing $1.258 billion. Gross margin is stable at 77.6%, operating margin is 29.84%, and TTM free cash flow is $1.434 billion. The balance sheet is fortress-like with debt-to-equity of 0.068 and $2.91 billion in cash. The forward PE of 26.40x is reasonable for a company with double-digit growth and a wide moat, especially compared to the trailing PE of 46.33x, which is distorted by temporary tax and one-time charges.
Key risks include the concentration in TAVR (72% of sales), potential margin pressure from rising R&D, and the possibility that the earnings recovery does not materialize as expected. The rating would change to Hold if revenue growth decelerates below 10% or if gross margin falls below 75%. It would upgrade to Strong Buy if the Medicare coverage expansion is finalized and TAVR growth accelerates above 15%. Relative to its history, the PS ratio of 8.22x is near the low end of its multi-year range, while the forward PE of 26.40x suggests the stock is fairly valued to slightly undervalued given its growth prospects.
Sign up to view all
EW 12-Month Price Forecast
EW presents a compelling growth story with a dominant TAVR franchise, double-digit revenue growth, and a potential Medicare coverage expansion catalyst. The valuation is reasonable on a forward basis (26.40x), and the balance sheet provides flexibility. However, the stock's premium multiple and revenue concentration warrant caution. We would upgrade to high confidence if the Medicare expansion is finalized and TAVR growth accelerates; we would downgrade to neutral if revenue growth decelerates below 10% or margins contract significantly.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Edwards Lifesciences's 12-month outlook, with a consensus price target around $101.87 and implied upside of +7.9% versus the current price.
Average Target
$101.87
0 analysts
Implied Upside
+7.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$84 - $117
Analyst target range
Coverage is deep and overwhelmingly constructive, with 27 analysts and a consensus recommendation of "buy" (mean rating of 1.63 on a 1-to-5 scale where lower is more bullish). The average target price of $101.39 implies roughly +13.8% upside from the current $89.07, and the consensus EPS estimate of $4.62 against a forward PE of 26.40x confirms that analysts are modeling a meaningful earnings recovery. The distribution of recent institutional ratings is uniformly positive — BTIG (Buy), Piper Sandler (Overweight), JP Morgan (Overweight), Mizuho (Outperform), RBC (Outperform), Citigroup (Buy), and Evercore (Outperform) — with Truist the lone Hold, and the notable upgrade from Leerink Partners to Outperform from Market Perform on July 24, 2026 signals improving sentiment rather than deteriorating conviction. The target range of $84.00 to $110.00 is moderately wide, spanning about 29% from low to high, which reflects genuine uncertainty around the pace of TAVR adoption and the timing of the Medicare coverage expansion. The $110 high target likely assumes accelerating TAVR volumes post-coverage expansion, successful mitral/tricuspid commercialization, and multiple expansion back toward the upper end of the historical band, while the $84 low target — only about 6% below the current price — prices in margin compression from rising R&D spend and competitive pressure in aortic valves. Notably, the low target sits above the 52-week low of $74.66, suggesting analysts see limited downside from here, and the tight clustering of ratings around Buy/Outperform with no Sell ratings indicates strong conviction in the structural heart franchise despite near-term earnings noise.
Drowning in data?
Find the real signal!
Bulls vs Bears: EW Investment Factors
The bull case rests on Edwards' dominant TAVR franchise, double-digit revenue growth, fortress balance sheet, and a potential Medicare coverage expansion that could unlock a larger patient pool. The bear case centers on the elevated trailing valuation, distorted earnings quality, margin pressure from R&D investment, and revenue concentration. Currently, the bull evidence appears stronger: revenue growth is accelerating, margins are stable at high levels, and analyst sentiment is overwhelmingly positive with a $101.39 average target. The single most important tension is whether the projected earnings recovery (forward PE of 26.40x vs. trailing 46.33x) materializes; if it does, the stock is reasonably valued, but any shortfall could lead to multiple compression.
Bullish
- TAVR dominance drives double-digit growth: Q2 2026 revenue of $1.741 billion grew 13.63% YoY, with TAVR contributing $1.258 billion—72% of total sales. The five-quarter trajectory from $1.413 billion in Q1 2025 to $1.741 billion in Q2 2026 implies roughly 23% cumulative growth, demonstrating durable demand for the core aortic valve franchise.
- Medicare coverage expansion is a major catalyst: A proposed U.S. agency expansion of Medicare coverage for TAVR procedures could significantly broaden the eligible patient pool. As the market leader with first-mover scale and clinical evidence, Edwards is best positioned to capture incremental procedure volumes, which analysts likely embed in the $110 high target.
- Fortress balance sheet with strong cash generation: Debt-to-equity is just 0.068, current ratio is 3.72, and cash stands at $2.91 billion. TTM free cash flow of $1.434 billion—including $585 million in Q2 2026 alone—provides ample funding for R&D, buybacks ($521.8 million in Q1 2026), and potential tuck-in acquisitions without financial strain.
- Premium margins reflect pricing power: Gross margin has been stable in the 77.6%–78.3% band over the last four quarters, and operating margin was 29.84% in Q2 2026. These levels are well above the broader medical device sector (typically 55%–65% gross margin), supporting the premium valuation and indicating strong pricing power and efficient manufacturing.
Bearish
- Elevated trailing valuation despite forward optimism: The trailing PE of 46.33x is well above the market average and sits in the middle-to-upper portion of EW's historical range (28x–134x). While the forward PE of 26.40x implies a significant earnings step-up, any disappointment in that recovery could trigger multiple compression.
- Earnings quality distorted by tax and one-time charges: Q2 2026 net margin was only 13.89% due to a 53.6% effective tax rate, and Q4 2025 net margin was 5.81% due to a $279.9 million other-expense charge. These distortions make trailing earnings unreliable and raise questions about the sustainability of the projected EPS recovery to $4.62.
- Margin pressure from rising R&D and SG&A: Operating margin compressed to 29.84% in Q2 2026 from 31.22% in Q1 2026, driven by higher R&D ($278.9 million) and SG&A ($561.2 million). Continued investment in mitral and tricuspid franchises may keep margins under pressure, limiting earnings growth.
- Revenue concentration in TAVR: TAVR accounts for 72% of total revenue ($1.258 billion of $1.741 billion), leaving the company highly dependent on aortic valve procedure volumes. Any slowdown in TAVR adoption, competitive erosion, or reimbursement changes could disproportionately impact results.
EW Technical Analysis
EW is in a constructive but choppy uptrend, with the stock up 16.39% over the trailing year and trading at roughly 89.07, which places it at about 66.5% of its 52-week range of 74.66 to 96.29. That positioning is neither extended nor washed out — the stock has recovered meaningfully from its 52-week low but remains about 7.5% below its 52-week high, suggesting a market that has rewarded the fundamental story without yet pricing in a full breakout. The 6-month gain of 5.85% versus the 1-year gain of 16.39% indicates the bulk of the advance occurred earlier in the period, with the stock consolidating in a broad 82–96 band since mid-year. Recent momentum is re-accelerating: the 1-month change of +2.59% and 3-month change of +7.79% both outpace the 6-month figure, and relative strength versus SPY is positive across 1-month (+3.61), 3-month (+4.94), and 1-year (+3.26) windows, though YTD relative strength of -7.07 shows EW lagged the market through the first half. The stock's most recent close of 89.07 sits just below the 90.09 prior close after a -1.13% pullback, and the 2.78 short ratio suggests short sellers are not aggressively positioned, leaving room for momentum continuation. Key resistance sits at the 96.29 52-week high, and a decisive breakout above that level would confirm a new leg higher and likely draw trend-following capital; support rests at the 74.66 52-week low, with intermediate support around the 82–84 zone where the stock repeatedly found buyers in July and September. A beta of 0.864 means EW is roughly 14% less volatile than the market, which supports larger position sizing for risk-adjusted exposure, while the -13.19% max drawdown over the period underscores that even low-beta medtech names can experience sharp air pockets around earnings and reimbursement headlines.
Beta
0.86
0.86x market volatility
Max Drawdown
-13.2%
Largest decline past year
52-Week Range
$75-$96
Price range past year
Annual Return
+14.2%
Cumulative gain past year
| Period | EW Return | S&P 500 |
|---|---|---|
| 1m | +7.2% | +0.7% |
| 3m | +9.7% | +3.0% |
| 6m | +12.5% | +6.8% |
| 1y | +14.2% | +11.9% |
| ytd | +10.7% | +12.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EW Fundamental Analysis
Revenue is growing at a healthy clip, with Q2 2026 revenue of $1.741 billion representing 13.63% year-over-year growth versus Q2 2025's $1.532 billion, and the sequential progression from $1.649 billion in Q1 2026 confirms steady expansion rather than a one-quarter spike. Segment data shows TAVR remains the engine at $1.258 billion, dwarfing Transcatheter Mitral and Tricuspid Therapies at $198.6 million and Surgical at $284.1 million, meaning the investment case is overwhelmingly levered to aortic valve procedure volumes and the Medicare coverage expansion catalyst. The trajectory from $1.413 billion in Q1 2025 to $1.741 billion in Q2 2026 — roughly 23% growth over five quarters — implies the growth rate is stable to accelerating, which is the key support for the premium multiple. Profitability is solid but uneven: Q2 2026 net income of $241.9 million on a 13.89% net margin was pressured by a 53.6% effective tax rate, while Q1 2026 delivered $380.7 million at a 23.09% net margin and Q4 2025 was unusually weak at $91.2 million (5.81% margin) due to a $279.9 million other-expense charge. Gross margin has been remarkably stable in the 77.6%–78.3% band across the last four quarters, consistent with best-in-class medtech device economics, and operating margin of 29.84% in Q2 2026 versus 31.22% in Q1 reflects modest compression from higher R&D ($278.9 million) and SG&A ($561.2 million). The balance sheet is fortress-like: debt-to-equity of just 0.068, a current ratio of 3.72, and $2.91 billion in cash at the end of Q2 2026 give the company ample internal funding capacity. Free cash flow is robust at $1.434 billion TTM, with Q2 2026 alone generating $585 million of FCF on $651.9 million of operating cash flow against only $66.9 million of capex, though Q1 2026 FCF was negative $21.1 million due to a $501.5 million working-capital swing. ROE of 10.38% and ROA of 8.37% are respectable but below the company's historical norms, reflecting the tax and one-time charge noise, and the absence of a dividend (payout ratio of 0) means all cash is reinvested or returned via buybacks, which totaled $521.8 million in Q1 2026.
Quarterly Revenue
$1.7B
2026-06
Revenue YoY Growth
+13.6%
YoY Comparison
Gross Margin
77.6%
Latest Quarter
Free Cash Flow
$1.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EW Overvalued?
Because EW is profitable with positive net income, the PE ratio is the appropriate primary metric, and the trailing PE of 46.33x versus a forward PE of 26.40x is the single most important valuation signal in this dataset. The 43% compression between trailing and forward multiples implies the market expects a substantial earnings step-up — consistent with consensus EPS of $4.62 versus the current trailing figure — and reflects that trailing earnings are temporarily depressed by the elevated tax rate and one-time charges rather than any structural deterioration. On a price-to-sales basis, EW trades at 8.22x, with an EV/Sales of 7.36x and EV/EBITDA of 33.31x, all of which sit at premium levels typical of high-growth, high-margin medtech franchises. Peer comparison is constrained by the absence of an explicit industry-average multiple in the provided valuation data, but the internal spread is instructive: a 78.1% gross margin and 26.97% operating margin justify a premium to the broader medical devices sector, where gross margins typically run in the 55%–65% range, and the 8.22x PS multiple is consistent with a market leader growing low-to-mid teens. The PEG ratio of -0.63 is not meaningful given the earnings distortion and should be disregarded. Historically, EW's PE has ranged from roughly 28x to 134x over the past several years, with the current 46.33x trailing reading sitting in the middle-to-upper portion of that band, while the PS ratio of 8.22x is well below the 29x–60x readings seen in 2021–2022 and near the low end of its multi-year range. That divergence — elevated trailing PE but compressed PS — tells the story: the market is no longer paying a bubble-era sales multiple, but earnings quality is temporarily impaired, so the forward PE of 26.40x is the cleanest read and suggests the stock is reasonably valued for a franchise with double-digit growth and dominant market position.
PE
46.3x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 27x~60x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
33.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are moderate. The company carries minimal debt (debt-to-equity of 0.068) and has a strong cash position of $2.91 billion, but earnings quality has been volatile: Q2 2026 net margin was 13.89% due to a 53.6% effective tax rate, and Q4 2025 net margin was 5.81% due to a $279.9 million other-expense charge. Additionally, revenue is heavily concentrated in TAVR (72% of sales), making the company vulnerable to any slowdown in aortic valve procedures. R&D spending is rising ($278.9 million in Q2 2026 vs. $263.3 million in Q1 2026) to support mitral and tricuspid franchises, which may pressure margins in the near term.
Market and competitive risks include valuation compression and competitive threats. EW trades at a trailing PE of 46.33x and a forward PE of 26.40x, which is a premium to the broader market and leaves little room for disappointment. The medical device sector is highly competitive, and while Edwards leads in TAVR, competitors are investing in transcatheter mitral and tricuspid therapies. Regulatory headwinds, such as potential changes to Medicare reimbursement, could also impact adoption. The stock's beta of 0.864 indicates lower volatility than the market, but sector rotation away from growth medtech could still pressure shares.
In a worst-case scenario, a combination of slower TAVR growth, margin compression from rising R&D, and a delay in Medicare coverage expansion could drive the stock down to its 52-week low of $74.66, representing a 16.2% decline from the current price of $89.07. The analyst low target of $84 implies a 5.7% downside, but a more severe scenario could see the stock test the low $70s if earnings fail to meet the $4.62 consensus and the forward PE contracts toward 20x. Investors could lose 16%–20% in such an adverse scenario.
FAQ
The most severe risk is revenue concentration: TAVR accounts for 72% of sales, so any slowdown in aortic valve procedures or competitive erosion could significantly impact results. Second, earnings quality is a concern, with Q2 2026 net margin at 13.89% due to a 53.6% tax rate and Q4 2025 net margin at 5.81% due to a $279.9 million charge, making trailing earnings unreliable. Third, margin pressure from rising R&D ($278.9 million in Q2 2026) could limit earnings growth. Finally, regulatory risk: the Medicare coverage expansion may be delayed or altered, which would remove a key catalyst. These risks are ranked from most to least severe.
Our 12-month forecast has three scenarios: Bull (25% probability) targeting $105–$110, Base (55%) targeting $95–$105, and Bear (20%) targeting $75–$84. The base case is most likely, assuming TAVR growth of 12-14%, stable margins, and the Medicare coverage expansion proceeding. This aligns with the analyst average target of $101.39. The key assumption is that earnings meet the $4.62 consensus, which would justify the forward PE of 26.40x. If the coverage expansion is finalized sooner or TAVR growth accelerates, the bull case could play out; if growth slows or margins compress, the bear case is possible.
EW appears fairly valued to slightly undervalued on a forward basis. The trailing PE of 46.33x is elevated, but it is distorted by temporary tax and one-time charges; the forward PE of 26.40x is more representative and is in line with a company growing earnings at a mid-teens pace. The PS ratio of 8.22x is near the low end of its historical range (29x–60x in 2021–2022), suggesting the market is no longer paying a bubble-era multiple. Compared to peers, EW's 78% gross margin and 27% operating margin justify a premium. The market expects earnings to recover to $4.62 per share, and if that materializes, the stock is reasonably priced.
EW offers a favorable risk/reward for growth-oriented investors. The stock trades at $89.07, about 13.8% below the analyst average target of $101.39, with a forward PE of 26.40x that is reasonable for a company growing revenue at 13.6% and generating $1.43 billion in free cash flow. The biggest downside risk is a delay in the Medicare coverage expansion or a TAVR growth slowdown, which could push the stock to the $84 low target (5.7% downside) or the 52-week low of $74.66 (16.2% downside). Given the strong fundamentals and positive analyst sentiment, EW is a good buy for long-term investors who can tolerate short-term volatility, but near-term upside may be limited until the coverage expansion is finalized.
EW is best suited for long-term investment, given its dominant market position, strong balance sheet, and long runway for TAVR adoption. The stock has a beta of 0.864, indicating lower volatility than the market, but it can experience sharp moves around earnings and reimbursement news (max drawdown of -13.19% over the period). The absence of a dividend means returns depend on capital appreciation, which is tied to earnings growth and multiple expansion. Short-term trading is less attractive due to the lack of clear momentum and the binary nature of the Medicare coverage catalyst. We recommend a minimum holding period of 2-3 years to allow for the full realization of the TAVR opportunity and the pipeline.